F2G

Based in the United Kingdom, F2G is a startup. Its most recent tracked round is Series B. Brouky records 6 investors associated with the company.

F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. The company has discovered and developed a completely new class of antifungal agents called the orotomides, which selectively target a key enzyme in the de novo pyrimidine biosynthesis pathway.